ZA864571B - N-(2-aminoacylamido-2-deoxy-hexosyl)-amides,-carbamates and-ureas,processes for their preparation,and their use in medicaments - Google Patents

N-(2-aminoacylamido-2-deoxy-hexosyl)-amides,-carbamates and-ureas,processes for their preparation,and their use in medicaments

Info

Publication number
ZA864571B
ZA864571B ZA864571A ZA864571A ZA864571B ZA 864571 B ZA864571 B ZA 864571B ZA 864571 A ZA864571 A ZA 864571A ZA 864571 A ZA864571 A ZA 864571A ZA 864571 B ZA864571 B ZA 864571B
Authority
ZA
South Africa
Prior art keywords
denotes hydrogen
carbon atoms
alkyl radical
hydrogen
aminoacylamido
Prior art date
Application number
ZA864571A
Other languages
English (en)
Inventor
Oswald Lockhoff
Yutaka Hayauchi
Peter Stadler
Klaus Georg Stuenkel
Gert Streissle
Arnold Paessens
Volker Klimetzek
Hans-Joachim Zeiler
Karl Georg Metzger
Hein-Peter Kroll
Helmut Brunner
Klaus Schaller
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA864571B publication Critical patent/ZA864571B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Seasonings (AREA)
  • Hydrogenated Pyridines (AREA)
ZA864571A 1985-06-20 1986-06-19 N-(2-aminoacylamido-2-deoxy-hexosyl)-amides,-carbamates and-ureas,processes for their preparation,and their use in medicaments ZA864571B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853521994 DE3521994A1 (de) 1985-06-20 1985-06-20 N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
ZA864571B true ZA864571B (en) 1987-02-25

Family

ID=6273684

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA864571A ZA864571B (en) 1985-06-20 1986-06-19 N-(2-aminoacylamido-2-deoxy-hexosyl)-amides,-carbamates and-ureas,processes for their preparation,and their use in medicaments

Country Status (21)

Country Link
US (1) US4855283A (fr)
EP (1) EP0206037B1 (fr)
JP (1) JPH07116207B2 (fr)
KR (1) KR930011281B1 (fr)
CN (1) CN86104185A (fr)
AT (1) ATE71631T1 (fr)
AU (1) AU564222B2 (fr)
CA (1) CA1289952C (fr)
CS (1) CS270209B2 (fr)
DE (2) DE3521994A1 (fr)
DK (1) DK287886A (fr)
ES (2) ES8801769A1 (fr)
FI (1) FI84833C (fr)
GR (1) GR861574B (fr)
HU (1) HU206123B (fr)
IE (1) IE58918B1 (fr)
IL (1) IL79126A (fr)
NO (1) NO166002C (fr)
PH (1) PH26775A (fr)
PT (1) PT82796B (fr)
ZA (1) ZA864571B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US5977336A (en) * 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
US5905071A (en) * 1993-08-30 1999-05-18 Bayer Aktiengesellschaft Glycosylamides of 2-aminoacylamino-2-deoxy sugars
NZ275772A (en) * 1993-11-08 1998-04-27 Connaught Lab Haemophilus transferrin receptor genes and proteins including production and use
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
ATE221081T1 (de) 1995-05-04 2002-08-15 Aventis Pasteur Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
US5827654A (en) * 1995-05-08 1998-10-27 University Of Toronto Basal body rod protein genes of campylobacter
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
US6048539A (en) * 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
FR2746643B1 (fr) * 1996-04-01 1998-06-12 Techni Pharma Nouvelles compositions laxatives et leur procede de fabrication
BRPI9710460B8 (pt) 1996-07-02 2021-05-25 Aventis Pasteur composição imunogênica multi-valente e composição de vacina
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
JP2002505665A (ja) * 1997-04-30 2002-02-19 メリュー・オラバックス Ｔｈ１型アジュバントを含有する抗ヘリコバクターワクチン組成物
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US5977337A (en) * 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6335182B1 (en) 1999-03-16 2002-01-01 Aventis Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US7785609B1 (en) 1999-03-16 2010-08-31 Sanofi Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
AUPS143402A0 (en) * 2002-03-28 2002-05-09 Alchemia Pty Ltd Anomeric derivatives of monosaccharides
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
ES2352671T3 (es) * 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
SI1633189T1 (sl) 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
UA90569C2 (ru) * 2006-01-26 2010-05-11 Пфайзер Продактс Инк. Композиция гликолипидного адьюванта (варианты) и способ ее получения
ME00045B (fr) * 2006-01-26 2010-10-10 Zoetis Services Llc Nouvelles compositions auxiliaires de glycolipide
HUE025225T2 (en) 2007-02-23 2016-02-29 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic diseases
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
GB2450088A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Optionally modified monosaccharides with imine/iminium or glycosidic amine/ammonium group for use in modifying the level of cytokines & in therapy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
EP2196196A1 (fr) 2008-12-10 2010-06-16 Medipol S.A. Composé, médicament, composition de vaccin et nanocapsules
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination
EP3705133B1 (fr) 2010-05-14 2024-06-26 Baxalta Incorporated Chimères d'ospa et leur utilisation dans des vaccins
JP2015524802A (ja) 2012-07-27 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ キメラｏｓｐａ分子を含む組成物およびその使用方法
CN104628802B (zh) * 2013-11-07 2017-01-18 北大方正集团有限公司 从发酵液中提取并纯化尼莫克汀的方法
EP3071974A2 (fr) 2013-11-19 2016-09-28 Prothena Biosciences Limited Suivi d'une immunothérapie de maladie à corps de lewy d'après des symptômes de constipation
EP3028711A1 (fr) * 2014-12-05 2016-06-08 Gubra ApS Blocs de construction moléculaire capable d'assembler des dérivés d'hydrates de carbone, de résidus d'acide gras et de peptides
AU2016297529B2 (en) * 2015-07-20 2021-09-09 Zoetis Services Llc Liposomal adjuvant compositions
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213650A1 (de) * 1982-04-14 1983-10-27 Bayer Ag, 5090 Leverkusen N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr
DE3344257A1 (de) * 1983-12-07 1985-06-13 Bayer Ag, 5090 Leverkusen Substituierte o-acyl-glycosylamide, verfahren zu iherer herstellung sowie ihre verwendung

Also Published As

Publication number Publication date
AU564222B2 (en) 1987-08-06
IE58918B1 (en) 1993-12-01
PT82796A (en) 1986-07-01
ES557729A0 (es) 1989-04-16
KR870000354A (ko) 1987-02-18
FI862619A7 (fi) 1986-12-21
DK287886A (da) 1986-12-21
DE3683410D1 (de) 1992-02-27
ES8801769A1 (es) 1988-02-16
FI862619A0 (fi) 1986-06-18
HU206123B (en) 1992-08-28
ES556287A0 (es) 1988-02-16
US4855283A (en) 1989-08-08
NO862199L (no) 1986-12-22
NO862199D0 (no) 1986-06-03
EP0206037A2 (fr) 1986-12-30
NO166002B (no) 1991-02-04
PH26775A (en) 1992-10-13
ES8900231A1 (es) 1989-04-16
KR930011281B1 (en) 1993-11-29
FI84833B (fi) 1991-10-15
JPS61293991A (ja) 1986-12-24
EP0206037A3 (en) 1988-02-03
ATE71631T1 (de) 1992-02-15
EP0206037B1 (fr) 1992-01-15
FI84833C (fi) 1992-01-27
AU5897986A (en) 1986-12-24
DK287886D0 (da) 1986-06-19
CS451386A2 (en) 1989-10-13
DE3521994A1 (de) 1987-01-02
CS270209B2 (en) 1990-06-13
IL79126A0 (en) 1986-09-30
CN86104185A (zh) 1987-04-08
GR861574B (en) 1986-10-17
HUT41049A (en) 1987-03-30
CA1289952C (fr) 1991-10-01
IE861636L (en) 1986-12-20
JPH07116207B2 (ja) 1995-12-13
PT82796B (pt) 1988-12-15
NO166002C (no) 1991-05-15
IL79126A (en) 1991-09-16

Similar Documents

Publication Publication Date Title
ZA864571B (en) N-(2-aminoacylamido-2-deoxy-hexosyl)-amides,-carbamates and-ureas,processes for their preparation,and their use in medicaments
MX9203744A (es) Analogos de camptotecina solubles en agua utiles para inhibir el crecimiento de celulas de tumor de animal.
GR78496B (fr)
DE3062609D1 (en) Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds
EP0632036A3 (fr) Dérivés d'amide et d'urée ayant un activité anti-hypercholestérolémique, leur préparation et leurs applications thérapeutiques
MY106314A (en) New tetrazole derivatives, process for their preparation and their use
GR3021500T3 (en) Potentiating cell-mediated immunity utilizing polyamine derivatives
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
ZA831193B (en) Dibenzocycloheptenylidene compounds for use in modulating the immune response
DK0609310T3 (da) N-(mercaptoacyl)aminosyrer, fremgangsmåder til fremstilling og terapeutisk anvendelse deraf og farmaceutiske sammensætninge
ES485828A1 (es) Procedimiento para la preparacion de piridazinas substitui- das
FR2455037A1 (fr) Medicament freinateur des activites hypophysaires